Next-generation multiple myeloma treatment: a pharmacoeconomic perspective - ScienceDirect
CASTOR study design. RRMM = relapsed or refractory multiple myeloma;... | Download Scientific Diagram
Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US | SpringerLink
Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up† - Annals of Oncology
The DVD Regimen After Myeloma Progression
A Single Centre Review of Bortezomib Home-Administration in Myeloma Patients: Portsmouth Experience
Doxil, Vincritine, Reduced Frequency Dexamethasone in Combination with Thalidomide (DVd-T) Is Associated with Higher Overall and Progression Free Survival as Compared to DVd in Patients with Multiple Myeloma (MM). - ScienceDirect
Treatment of relapsed and refractory multiple myeloma | Haematologica
SYNOPSIS
Hull University Teaching Hospitals and North Lincolnshire NHS Trusts Haematology Multidisciplinary Team Guideline and Pathway Mu
Comparative Efficacy of Treatments for Previously Treated Multiple Myeloma: A Systematic Literature Review and Network Meta-analysis - ScienceDirect
Multiple myeloma current treatment algorithms | Blood Cancer Journal
Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study - Yimer - 2019 - British Journal of Haematology - Wiley Online Library
Addition of daratumumab to multiple myeloma backbone regimens significantly improves clinical outcomes: a systematic review and meta-analysis of randomised controlled trials | Scientific Reports
Best Practice for the Administration of Daratumumab in Multiple Myeloma: Australian Myeloma Nurse Expert Opinion
Frontiers | Efficacy of Daratumumab-Containing Regimens Among Patients With Multiple Myeloma Progressing on Lenalidomide Maintenance: Retrospective Analysis
Is it feasible to conduct a randomised controlled trial of pretransplant exercise (prehabilitation) for patients with multiple myeloma awaiting autologous haematopoietic stem cell transplantation? Protocol for the PREeMPT study | BMJ Open
Approved for use in:
Hemato | Free Full-Text | Why Immunotherapy Fails in Multiple Myeloma
Best Practice for the Administration of Daratumumab in Multiple Myeloma: Australian Myeloma Nurse Expert Opinion
DVdSC (weekly cycles1-8) Bortezomib-Daratumumab-Dexamethasone Ver1
Multiple myeloma current treatment algorithms | Blood Cancer Journal
CASTOR study design. RRMM = relapsed or refractory multiple myeloma;... | Download Scientific Diagram
Pharmaceuticals | Free Full-Text | Monoclonal Antibodies: Leading Actors in the Relapsed/Refractory Multiple Myeloma Treatment
